683 Capital Management LLC Acquires New Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

683 Capital Management LLC acquired a new position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 163,109 shares of the company's stock, valued at approximately $522,000. 683 Capital Management LLC owned about 0.33% of Checkpoint Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of CKPT. Virtu Financial LLC purchased a new position in shares of Checkpoint Therapeutics during the third quarter valued at approximately $30,000. SBI Securities Co. Ltd. bought a new stake in Checkpoint Therapeutics in the fourth quarter valued at $32,000. PUREfi Wealth LLC purchased a new position in Checkpoint Therapeutics during the 4th quarter valued at $32,000. Stifel Financial Corp bought a new position in Checkpoint Therapeutics in the 4th quarter worth $32,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock worth $34,000 after purchasing an additional 6,486 shares during the period. 22.00% of the stock is owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Stock Performance

Shares of CKPT stock traded down $0.01 during mid-day trading on Tuesday, reaching $4.15. 445,765 shares of the company's stock traded hands, compared to its average volume of 1,253,966. Checkpoint Therapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $4.50. The firm has a 50 day moving average price of $3.83 and a two-hundred day moving average price of $3.58. The firm has a market capitalization of $347.20 million, a PE ratio of -2.25 and a beta of 1.18.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47). The company had revenue of $0.04 million for the quarter. As a group, equities analysts expect that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Insider Transactions at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 12,322 shares of Checkpoint Therapeutics stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total value of $49,904.10. Following the transaction, the chief financial officer now directly owns 1,446,322 shares in the company, valued at approximately $5,857,604.10. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of Checkpoint Therapeutics stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the completion of the transaction, the chief executive officer now owns 3,775,019 shares in the company, valued at $11,891,309.85. This trade represents a 0.27 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 121,086 shares of company stock worth $446,879. 2.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Lake Street Capital restated a "hold" rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. D. Boral Capital reaffirmed a "buy" rating and issued a $4.80 target price on shares of Checkpoint Therapeutics in a research report on Monday, March 31st. Finally, HC Wainwright reissued a "neutral" rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.